In conclusion, this study clearly showed that plasma-based CCND1 copy number provides a valuable biomarker for monitoring treatment efficacy and predicting both the associated clinical factors and prognosis of ESCC. The gene discussed is CCND1; the disease is esophageal squamous cell carcinoma.